SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
申请人:UNIVERSITY OF TSUKUBA
公开号:US20180179151A1
公开(公告)日:2018-06-28
The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
The reaction between carboxylic acids (RCOOH) and dialkyl dicarbonates [(R 1 OCO) 2 O], in the presence of a weak Lewis acid such as magnesium chloride and the corresponding alcohol (R 1 OH) as the solvent, leads to the esters RCOOR 1 in excellent yields. The mechanism involves a double addition of the acid to the dicarbonate, affording a carboxylic anhydride [(RCO) 2 O], R 1 OH and carbon dioxide
selectivity and drug-like properties of CDK inhibitors, safety of multi-target inhibitors remains a significant challenge. Macrocyclization is a promising drug discovery strategy to improve the pharmacological properties of existing compounds. Here we report the development of a macrocyclization platform that enabled the highly efficient discovery of a novel, macrocyclic CDK2/4/6 inhibitor from an
The optically active allene macrodiolides via the macrocyclization of allenic ester provide a simple route to (−)-pyrenophorin and (+)-dibenzomacrodiolide, respectively.